Completed PHASE1 INTERVENTIONAL 2-arm NCT04214808

To Evaluate the Pharmacokinetics and Safety of AD-208

A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of AD-208

Sponsor: Addpharma Inc.

Interventions AD-208 Avodart Soft Capsule 0.5mg

Updated 5 times since 2020 Last updated: Dec 1, 2020 Started: Jan 3, 2020 Primary completion: Feb 4, 2020 Completion: May 4, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Androgenetic Alopecia and is currently completed. Addpharma Inc. leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Addpharma Inc.

Data source: Addpharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Daegu, South Korea